Led · Seed · Jun 2026

Filament Sciences was launched and bootstrapped by founder Nathan Puksta, a L'Oréal veteran, and positions itself as a professional, science-led hair care brand emphasizing scalp health. The company proved product-market fit and early distribution traction before raising external capital. It has just closed a $2 million seed round to support scaling inventory and expanding into the salon professional channel. Filament also plans to invest in education as part of its growth strategy for professionals. The financing marks the company’s shift from founder-funded to partner-backed growth while keeping a tightly controlled cap table.

Led · Seed · Apr 2026

ViewsML develops an AI-driven virtual biomarker staining platform that virtualizes immunohistochemistry to deliver per-cell spatial biomarker insights from standard H&E slides. The platform is intended to preserve scarce tissue samples while accelerating research, clinical trials, and patient care. ViewsML is building a virtual biomarker library comprised of AI models that extract biomarker information directly from routine pathology images. The company has established strategic collaborations with healthcare institutions, diagnostic companies, and biopharma organizations to drive adoption across research and clinical applications. Led by CEO Kenneth To, ViewsML plans to use newly raised seed capital to commercialize the platform, expand partnerships, advance clinical validation of its virtual biomarker panels, and grow its engineering, scientific, and commercial teams.

Led · Series A · Feb 2026

Founded in 2021 and headquartered in Toronto, Shakudo sells software that lets companies integrate leading AI models into their existing tech stacks without the need for large DevOps teams. Enterprises in finance, healthcare, aerospace, energy, and retail—including Loblaw Digital—use Shakudo to cut AI development cycles from months to days. The 35-person company recently opened offices in Silicon Valley and Bangalore and launched an AI agent called Kaji, described as a virtual senior engineer that is both technically deep and business-minded. Management reports that revenue has grown seven-fold since mid-2023 and now sits "in the ballpark of a Series B company," while the business remains capital-efficient with a clear path to profitability. Fresh capital will fund additional computing capacity and selective engineering hires as Shakudo positions itself to raise a larger Series B round within the next one to two years.

Led · Series A · Nov 2025

WellBeam is a Redwood City–based healthcare technology company focused on improving care coordination between acute and post-acute providers through seamless interoperability and EMR integration. Its platform allows health systems, physician networks, and independent medical groups to exchange clinical data and manage clinical workflows without leaving their existing EMR environments. By embedding connectivity into current systems, WellBeam aims to reduce administrative friction and improve patient transitions of care. Led by co-founder and CEO Amee Devani, the company counts health systems, physician groups, and post-acute partners among its customers. WellBeam plans to use its newly raised capital to accelerate growth and broaden its interoperability infrastructure across additional health systems and physician groups. The recent financing marks a key milestone in scaling its technology and market reach. No revenue or user metrics were disclosed in the article.

Participated · Series A · Aug 2024

Noetik is an AI-native biotechnology company that combines self-supervised machine learning with high-throughput spatial omics and in vivo CRISPR perturbation to discover precision cancer therapies. Its discovery platform pairs human multimodal spatial omics data purpose-built for machine learning with a massively multiplexed in vivo CRISPR Perturb-Map system to train foundation models of tissue and tumor biology. The company has built one of the world’s largest spatial omics-based atlases of human cancer biology and trains multi-modal cancer foundation models such as OCTO. Proceeds from the recent Series A will be used to expand the atlas, scale Perturb-Map throughput, and increase training of its models. Noetik plans to leverage these platform capabilities to advance an innovative pipeline of cancer therapeutics candidates into the clinic and to establish strategic partnerships with academic institutions, health care providers, and pharmaceutical companies. The company is based in San Francisco and recently appointed Shafique Virani as Chief Business Officer to lead partnering efforts. Noetik has built a multimodal tissue profiling platform that combines self-supervised learning with spatial biology to address fundamental problems in cancer immunology. In under 12 months of operations the company has generated hundreds of terabytes of human data across genomics, transcriptomics, and proteomics to enable foundation models for cell and tissue biology. The company plans to use transformer-based machine learning methods applied to this internal data stack to accelerate target and therapeutics discovery. The recent funding will support substantial internal data generation efforts and continued development of those ML methods. Proceeds will also be used to expand Noetik’s team in machine learning, computational biology, and cancer immunology. Noetik is based in San Francisco and is led by CEO Ron Alfa, with founding leaders including CTO Lacey Padron and CSO Jacob Rinaldi.